MedTrace Logo

The ENABLE Study: Safety and Efficacy Study of INZ-701 in Patients With ENPP1 Deficiency

NCT06739980 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-05-01

No results posted yet for this study

Summary

The purpose of Study INZ701-108 (ENABLE) is to assess the safety and efficacy of INZ-701 in patients 1 year of age and older with ENPP1 Deficiency who have not previously received INZ-701 and are not eligible for existing Inozyme-sponsored clinical studies that are still open to enrollment.

Conditions

  • Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
  • Autosomal Recessive Hypophosphatemic Rickets
  • Generalized Arterial Calcification of Infancy 1

Interventions

DRUG

INZ-701

Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.

Sponsors & Collaborators

  • Inozyme Pharma

    lead INDUSTRY

Principal Investigators

  • Inozyme Pharma, Inc. · Inozyme Pharma, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-31
Primary Completion
2027-03-31
Completion
2028-03-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06739980 on ClinicalTrials.gov